The D3 trial is excited to announce that it has successfully completed recruitment in the trial at an exceptional speed. D3 is looking to see if a new tablet, a combination of two anti-HIV medicines, dolutegravir (DTG) and lamivudine (3TC), is as good and effective in treating HIV in children and young people living with HIV in comparison to the current paediatric anti-HIV medicines available.
The trial recruited 370 children from South Africa, Spain, Thailand, Uganda and the UK. Trial enrolment was guided and controlled by the MRC CTU and the rapid rate at which the recruitment was completed, is a testament to the appeal of a DTG/3TC drug and the dedication and commitment of the trial staff in finding more effective treatment options for children living with HIV.
Findings from this have the potential to significantly improve the lives of children living with HIV by reducing the pill burden and addressing long-term treatment challenges. Visit the D3 webpage to learn more.